Find policies, billing codes, payers, states, and providers
Voyxact (sibeprenlimab-szsl) — Prior authorization / medical necessity for primary IgA nephropathy
Customize your policy alerts
Sign up for all Colorado Rocky Mountain Health Plans policy alerts
Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and medical necessity criteria for Voyxact to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression; applies to Colorado Rocky Mountain Health Plans pharmacy benefit decisions.
Voyxact (sibeprenlimab-szsl) is included with prior authorization/medical necessity criteria.
SGLT2 step was removed from the program requirements.
Updated language in the steroid trial requirement.
Coverage Criteria for Voyxact (sibeprenlimab-szsl)
Initial Authorization
Covered when ALL of the following are met:
Stabilized dose requirement may be waived if contraindication or intolerance documented.
30-day steroid trial requirement.
Reauthorization
Covered when ALL of the following are met:
Authorization issued for 12 months if response shown.
Prior authorization is required for Voyxact and approvals are time-limited; initial and reauthorization approvals are issued for 12 months contingent on meeting the documentation and response requirements.
For reauthorization, documentation must demonstrate a positive clinical response shown by a reduction in proteinuria and continued fulfillment of eligibility criteria.
Therapy is covered only when the diagnosis of primary IgA nephropathy is confirmed by renal biopsy. Baseline renal function must meet the program threshold of eGFR ≥ 30 mL/min/1.73 m2 to be eligible for treatment.
Voyxact is intended to reduce proteinuria in patients at risk of rapid progression and must be prescribed either while the patient is on a stabilized, maximally tolerated ACE inhibitor or ARB (examples: captopril, enalapril, candesartan, valsartan) or when there is a documented contraindication or intolerance to ACE inhibitors/ARBs.
Patients must have a history of failure, contraindication, or intolerance to a glucocorticoid after a 30-day trial (examples include budesonide, methylprednisolone, prednisone) unless glucocorticoids are contraindicated or not tolerated.
Voyxact must be prescribed by or in consultation with a nephrologist. Failure to document biopsy confirmation, risk of rapid progression, baseline eGFR meeting the threshold, stabilized concomitant ACEi/ARB therapy (or contraindication), a completed 30-day steroid trial (or documented contraindication/intolerance), or nephrology involvement may render the request not medically necessary.
Referenced Coding and Key Clinical Thresholds
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required; 12‑month approvals
Prior authorization is required for Voyxact. Initial approvals are issued for 12 months; reauthorizations are also issued for 12 months and require documentation of a positive clinical response (reduction in proteinuria).
Concomitant ACEi/ARB required (or documented contraindication)
Patient must be on a stabilized dose and receiving concomitant therapy with a maximally tolerated ACE inhibitor or ARB, unless the patient has a documented contraindication or intolerance to ACE inhibitors and ARBs.
- Examples of ACE inhibitors: captopril, enalapril (document maximally tolerated dose).
- Examples of ARBs: candesartan, valsartan (document maximally tolerated dose).
- If contraindicated or intolerant to both ACEi and ARB, document the contraindication/intolerance.
Documentation required (initial and reauthorization)
Required documentation must be submitted with the prior authorization request and for reauthorization.
- Renal biopsy confirming primary IgA nephropathy.
- Evidence the patient is at risk of rapid disease progression.
- Baseline eGFR showing ≥ 30 mL/min/1.73 m2.
- Documentation of concomitant stabilized ACE inhibitor or ARB use, or documentation of contraindication/intolerance.
- Documentation of a 30‑day glucocorticoid trial failure, or contraindication/intolerance to glucocorticoids.
- Prescription by or documentation of consultation with a nephrologist.
- For reauthorization: documentation of reduction in proteinuria demonstrating positive clinical response.
Triggers for denial
The following conditions may trigger denial of coverage for Voyxact.
- No renal biopsy documentation confirming primary IgA nephropathy.
- No documentation that the patient is at risk of rapid disease progression.
- Baseline eGFR < 30 mL/min/1.73 m2.
- No documentation of stabilized concomitant ACE inhibitor or ARB therapy and no documented contraindication/intolerance.
- No documentation of a 30‑day glucocorticoid trial failure or documented contraindication/intolerance.
- Prescription not by or not in consultation with a nephrologist.
Definitions and Operational Terms
Background
The indication for Voyxact is limited to adults with primary immunoglobulin A nephropathy (primary IgAN) who are at risk of rapid disease progression. The long-term impact of Voyxact on slowing kidney function decline has not been established; continued approval may depend on confirmatory clinical trial evidence demonstrating clinical benefit. (See Initial Authorization and Reauthorization criteria for permitted uses and duration.)
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.